Article

IOL technology mimics 53-year-old crystalline lens

Jackson, MI-The new AcrySof Natural IOL (Model SB30AL, Alcon, Fort Worth, TX), which has a light transmission spectrum similar to that of a 53-year-old human crystalline lens, is the first of its kind that has become commercially available. It effectively filters blue light between 400 and 500 nm and preserves contrast sensitivity and color perception, according to Paul Ernest, MD.

Related Videos
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Related Content
Study: Diabetes does not significantly impact outcomes of epiretinal membrane surgery
Published: December 26th 2024 | Updated: December 26th 2024

Study: Diabetes does not significantly impact outcomes of epiretinal membrane surgery

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Melt Pharmaceuticals reports positive Phase 3 topline efficacy results for MELT-300
November 20th 2024

Melt Pharmaceuticals reports positive Phase 3 topline efficacy results for MELT-300

Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures
March 29th 2024

(EyePod) From idea to impact: Navigating ophthalmic innovation

Study explores the true costs of treating pediatric cataracts
November 12th 2024

Study explores the true costs of treating pediatric cataracts

Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007
November 6th 2024

Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007

© 2024 MJH Life Sciences

All rights reserved.